Meet Raphaël Geney

Raphaël manages a diverse portfolio of cases across multiple fields of chemistry, including pharmaceuticals and veterinary sciences, polymers, advanced materials, process engineering, agrifood, and cosmetics.
Raphaël’s expertise encompasses drafting and prosecuting patent applications and representing clients in opposition and appeal proceedings before the EPO. He provides strategic advice on patentability and freedom-to-operate issues and conducts validity assessments of third-party patents and applications.
Before transitioning to intellectual property, Raphaël pursued a career as a computational drug design scientist. He began his IP journey in the Intellectual Property Department of the biotech company Galapagos, then transitioned to a leading IP firm in Paris, before joining Gevers in 2025.

• Diploma of CEIPI (Patents), University of Strasbourg, France, 2016
• PhD in Organic Chemistry, Stony Brook University, USA, 2005
• MSc in Chemical Engineering, École supérieure de Chimie, Physique, Électronique de Lyon, France, 2001

• French Patent Attorney
• Professional Representative before the European Patent Office

• Mammoliti O, Menet C, Cottereaux C, Blanc J, De Blieck A, Coti G, Geney R, Oste L, Ostyn K, Palisse A, Quinton E, Schmitt B, Borgonovi M, Parent I, Jagerschmidt C, De Vos S, Vayssiere B, López-Ramos M, Shoji K, Brys R, Amantini D, Galien R, Joannesse C. Design of a potent and selective dual JAK1/TYK2 inhibitor. Bioorg Med Chem. 2024 Nov 15;114:117932.
• Brys R, Geney R, Joncour A, Doyon J, Labéguère F, Lefrançois J-M, Mammoliti O, Schmitt B, Van Der Plas S, Menet C. 6-[5-Amino-6-(2-ethoxyethoxy)-imidazo[4,5-b]pyridin-3-yl]-nicotinonitrile derivatives and their use as IRAK inhibitors. WO2017067848.
• Menet C, Fletcher S, van Lommen Guy, Geney R, Blanc J, Smits K, Jouannigot N, van der Aar E, Clement Lacroix P, Lepescheux L, Galien R, Vayssiere B, Nelles L, Christophe T, Brys R, Van Rompaey L, Ciesielski F, Uhring M. Triazolopyridine compounds as selective JAK1 inhibitors: from hit identification to GLPG0634. J Med Chem. 57(22):9323–42.
• Menet C, Schmitt B, Geney R, Doyle K, Peach J, Palmer N, Jones G, Hardy D, Duffy J. Imidazo[4,5-c]pyridine derivatives useful for the treatment of degenerative and inflammatory diseases. WO2013117649.
• Menet C, Schmitt B, Geney R, Doyle K, Peach J, Palmer N, Jones G, Hardy D, Duffy J. Imidazo[4,5-c]pyridine derivatives useful for the treatment of degenerative and inflammatory diseases. WO2013117645.
• Blanc J, Geney R, Menet C. Type II kinase inhibitors: an opportunity in cancer for rational design. Anticancer Agents Med Chem. 13(5):731-47.
• Menet C, Van Rompaey L, Geney R. Advances in the discovery of selective JAK inhibitors. Prog Med Chem. 52:153-223.
• Sun L, Geng X, Geney R, Li Y, Simmerling CL, Li Z, Lauher JW, Xia S, Horwitz SB, Veith JM, Pera P, Bernacki RJ, Ojima I. Design, Synthesis, and Biological Evaluation of Novel C14−C3′BzN-Linked Macrocyclic Taxoids. J Org Chem. 73(24):9584–93.
• Okur A, Wickstrom L, Layten M, Geney R, Song K, Hornak V, Simmerling CL. Improved efficiency of replica exchange simulations through use of a hybrid explicit/implicit solvation model. J Chem Theory Comput. 2(2):420-33.
• Geney R, Layten M, Gomperts R, Hornak V, Simmerling CL. Investigation of salt bridge stability in a generalized Born solvent model. J Chem Theory Comput. 2(1):115-27.
• Geney R, Sun L, Pera P, Bernacki RJ, Xia S, Horwitz SB, Simmerling CL, Ojima I. Use of the tubulin-bound paclitaxel conformation for structure-based rational drug design. Chem Biol. 12(3):339-48.
• Geney R, Chen J, Ojima I. Recent advances in the new generation taxane anticancer agents. Med Chem. 1(2):125-39.
• Geng X, Geney R, Pera P, Bernacki RJ, Ojima I. Design and synthesis of de novo cytotoxic alkaloids through mimicking taxoid skeleton. Bioorg Med Chem Lett. 14(13):3491-4.
• Ojima I, Geney R. 109881 Aventis. Curr Opin Investig Drugs. 4(6):737-40.
• Ojima I, Geney R. BMS-184476 Bristol-Myers Squibb. Curr Opin Investig Drugs. 4(6):732-6.
• Geney R, Ungureanu M, Li D, Ojima I. Overcoming multidrug resistance in taxane chemotherapy. Clin Chem Lab Med. 40(9):918-25.
• Ojima I, Geney R, Ungureanu IM, Li D. Medicinal chemistry and chemical biology of new generation taxane antitumor agents. IUBMB Life. 53(4-5):269-74.
• Chuang CY, Vassar VC, Ma Z, Geney R, Ojima I. Electronic effects on the regio- and enantioselectivity of the asymmetric aminohydroxylation of O-substituted 4-hydroxy-2-butenoates. Chirality. 14(2-3):151-62.